Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 3, 2019
- Accepted in final form January 23, 2020
- First Published March 13, 2020.
Author Disclosures
- Benoît Déchelotte, MD*,
- Sergio Muñiz-Castrillo, MD*,
- Bastien Joubert, MD,
- Alberto Vogrig, MD,
- Géraldine Picard, MSc,
- Véronique Rogemond, PhD,
- Anne-Laurie Pinto, MSc,
- Christine Lombard, PharmD,
- Virginie Desestret, MD, PhD,
- Nicole Fabien, PharmD, PhD and
- Jérôme Honnorat, MD, PhD
- Benoît Déchelotte, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Muñiz-Castrillo, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bastien Joubert, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology awarded the following grant: EAN Research Training Fellowship 2019
NONE
NONE
NONE
NONE
NONE
NONE
- Alberto Vogrig, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Géraldine Picard, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Véronique Rogemond, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Laurie Pinto, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Lombard, PharmD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginie Desestret, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicole Fabien, PharmD, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme Honnorat, MD, PhD
Scientific advisory board for Bristol Meyers Squibb
NONE
NONE
NONE
receives royalties from licensing fees to AthenaDiagnostics, Euroimmun, and ravo Diagnostika for a patentfor the use of CV2/CRMP5 as diagnostic tests.
NONE
NONE
NONE
NONE
NONE
NONE
Research support from CSL Behring France
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the French Reference Center on Paraneoplastic Neurological Syndromes (B.D., S.M.-C., B.J., A.V., G.P., V.R., A.-L.P., V.D., J.H.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (B.D., S.M.-C., B.J., A.V., G.P., V.R., A.-L.P., V.D., J.H.), Institute NeuroMyoGène, INSERM U1217/CNRS UMR5310, Université Claude Bernard Lyon 1; and Department of Immunology (B.D., C.L., N.F.), Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
- Correspondence
Dr. Honnorat jerome.honnorat{at}chu-lyon.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Paraneoplastic Cerebellar DegenerationThe Importance of Including CDR2L as a Diagnostic MarkerIda Herdlevær, Mette Haugen, Kibret Mazengia et al.Neurology: Neuroimmunology & Neuroinflammation, February 02, 2021 -
Articles
GABAB receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disordersA. Boronat, L. Sabater, A. Saiz et al.Neurology, February 28, 2011 -
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021 -
Article
Paraneoplastic MyeloneuropathiesClinical, Oncologic, and Serologic AccompanimentsShailee Shah, Rocio Vazquez Do Campo, Neeraj Kumar et al.Neurology, November 18, 2020